Vitamin B6 Interactions

Combined (estrogen-containing) oral contraceptives modestly lower the active form of vitamin B6, pyridoxal 5'-phosphate, by speeding up tryptophan metabolism. Long-term pill users tend to show lower B6 status markers than non-users. This is a depletion of a status marker rather than a clinical safety problem, and it does not affect how well the pill works.

Vitamin B6 and vitamin B12 act as complementary coenzymes in one-carbon metabolism: B12 helps remethylate homocysteine back to methionine, while B6 routes excess homocysteine down the transsulfuration pathway to cysteine. Taken together, they support both arms of homocysteine handling. Combination B-vitamin regimens lower homocysteine more reliably than single nutrients, though trials have not consistently shown reduced cardiovascular events.

Vitamin B6 and folate both work inside one-carbon metabolism, the network that recycles homocysteine and supplies methyl groups. Folate (as 5-MTHF) remethylates homocysteine back to methionine, while B6 (as PLP) is the cofactor for serine hydroxymethyltransferase, which feeds the folate cycle, and for cystathionine beta-synthase, which clears excess homocysteine through the transsulfuration pathway. Folate carries the main homocysteine-lowering effect; B6's contribution shows up mainly after a protein (methionine) load rather than in fasting levels.

Vitamin B6 and magnesium are nutritional partners: magnesium is needed to activate B6 into its coenzyme form, and B6 appears to support magnesium's uptake into cells. Randomized trials suggest the pair can ease premenstrual and stress-related symptoms somewhat better than magnesium alone, especially in people running low on magnesium. The effect is modest and beneficial, not a safety concern.

Levetiracetam (Keppra) commonly causes behavioral side effects including irritability, agitation, anxiety, and mood changes (sometimes called 'Keppra rage'). Randomized trials and case series in children and adults suggest that adding pyridoxine (vitamin B6) eases these behavioral symptoms in a meaningful subset of patients, though the evidence is mixed: two pediatric trials were positive while one adult trial was null. This is a potential benefit, not a harmful interaction.